India PCSK9-Targeted Therapy Market Size, Share, Growth, and Industry Analysis, By Drug Type / Modality (Monoclonal Antibodies (mAbs) Alirocumab Evolocumab, siRNA-based Therapies Inclisiran, Gene Editing and Other Novel Modalities CRISPR-based approaches Antisense oligonucleotides (ASOs) ), By Indication  (Heterozygous Familial Hypercholesterolemia (HeFH), Atherosclerotic Cardiovascular Disease (ASCVD), Homozygous Familial Hypercholesterolemia (HoFH), Hyperlipidemia (Non-FH) ) and Forecast, 2026-2034

India PCSK9-Targeted Therapy Market Trends

Long-Acting RNA Interference and One-Time Genetic Intervention Reshape LDL-C Management

PCSK9 therapy development is moving from repeated antibody injections toward longer-duration molecular interventions. Inclisiran established the RNA-interference concept of sustained PCSK9 suppression, while experimental base editing aims at a one-time intervention. In April 2025, VERVE-102 Phase 1b data covering 14 participants reported a mean LDL-C reduction of 53% and maximum reduction of 69% in the 0.6 mg/kg cohort, demonstrating the potential for genetic approaches to deliver substantial biological effects from a single infusion.

Technology competition is also extending toward oral PCSK9 inhibition. By July 2026, Merck's enlicitide had received U.S. approval as an oral PCSK9 inhibitor, with reported LDL-C lowering of up to approximately 60%, introducing a daily-tablet model alongside injections and long-acting RNA-based approaches. Meanwhile, 2026 reporting on VERVE-102 described a 35-patient Phase 1 program and reductions approaching 88% in circulating PCSK9 at the highest tested dose, underscoring a pipeline transition toward durable suppression rather than continuous dosing.

India PCSK9-Targeted Therapy Market Drivers

High Cardiovascular Risk and Persistent LDL-C Burden Support Advanced Lipid-Lowering Treatment

Cardiovascular risk, inadequate LDL-C control and inherited dyslipidemia create a sizeable addressable population for PCSK9-directed treatment. FH affects approximately 1 in 250–500 individuals globally, while Indian research reports FH among 15% of premature-CAD patients in the country's cited prevalence study. Indian genetic evidence identified LDLR mutations in 32%, ApoB mutations in 4% and PCSK9 mutations in 2% of reported cases, with 37% of the mutational spectrum remaining unknown. These figures reinforce demand for intensified lipid management among genetically predisposed and secondary-prevention populations.

India PCSK9-Targeted Therapy Market Restraints

High Treatment Intensity, Diagnosis Gaps and Access Requirements Limit Broad-Based Utilization

PCSK9-directed treatment remains concentrated in patients requiring substantial LDL-C reduction beyond conventional therapy. India's FH diagnostic infrastructure remains underdeveloped: published literature identified only 6 Indian genetic studies in the reviewed evidence base, while 37% of the reported mutational spectrum remained unidentified. PCSK9 mutations represented only 2% versus 32% for LDLR mutations, illustrating the complexity of genetic characterization. These diagnostic limitations, combined with injectable administration for established therapies and specialist-driven prescribing, constrain penetration into the much larger primary-care dyslipidemia population.

India PCSK9-Targeted Therapy Market Opportunities

RNA Interference, Oral Molecules and Gene Editing Expand the Treatable Patient Spectrum

Innovation can materially broaden PCSK9 targeting beyond conventional monoclonal antibodies. VERVE-102 generated a 53% mean LDL-C reduction and a maximum 69% reduction at 0.6 mg/kg among early Phase 1b participants, while subsequent reporting described PCSK9 reductions approaching 88% at higher dosing. Oral PCSK9 inhibition adds another delivery pathway, with enlicitide demonstrating LDL-C reductions around 60% in reported clinical evidence. Together, long-acting siRNA, oral molecules and potentially one-time gene editing could address adherence and administration barriers across high-risk patients.

Challenges in India PCSK9-Targeted Therapy Market

Evidence Generation and Patient Selection Become More Complex as Modalities Diversify

The competitive framework increasingly spans daily oral therapy, periodic injections and potentially permanent genetic modification. Early VERVE-102 evidence initially covered only 14 participants in the reported Phase 1b dataset, despite LDL-C reductions reaching 69% in the 0.6 mg/kg cohort. Indian genetic research has similarly operated with small cohorts; one PCSK9/LDLR study evaluated 50 FH cases against 50 controls and detected 8 nonpathogenic PCSK9 variants while identifying 3 known pathogenic LDLR variants. Scaling evidence across heterogeneous Indian populations therefore remains important for clinical positioning and reimbursement.

India PCSK9-Targeted Therapy Market Segmentation

The market is segmented by drug type/modality, indication, route of administration, distribution channel and patient type. Monoclonal antibodies account for approximately 45.6% of the supplied 2026 modality value, while HeFH represents approximately 44.5% of the supplied 2026 indication value. Gene editing and novel modalities post the fastest modality CAGR at 11.12%, whereas ASCVD records the fastest indication CAGR at 11.41%.

By Drug Type / Modality

Monoclonal antibodies, including alirocumab and evolocumab, form the largest modality category, increasing from USD 334.44 million in 2025 to USD 371.53 million in 2026 and USD 861.77 million by 2034 at 11.09% CAGR. Their 2026 contribution is approximately 45.6%, ahead of siRNA therapies at approximately 30.8%.

Gene editing and other novel modalities, including CRISPR-based approaches and ASOs, represent the fastest-growing supplied modality at 11.12% CAGR, rising from USD 192.33 million in 2026 to USD 447.07 million by 2034. SiRNA-based therapies, led by inclisiran, increase from USD 250.41 million to USD 577.48 million at 11.01% CAGR.

By Indication

HeFH is the largest indication, valued at USD 363.18 million in 2026 and forecast to reach USD 858.31 million in 2034 at 11.35% CAGR. It contributes approximately 44.5% of the supplied 2026 indication total, substantially exceeding ASCVD at USD 213.17 million.

ASCVD is the fastest-growing indication at 11.41% CAGR, reaching USD 505.97 million by 2034 from USD 213.17 million in 2026. HoFH advances at 10.86% CAGR to USD 355.80 million, while non-FH hyperlipidemia grows at 10.66% to USD 186.43 million.

By Route of Administration

Subcutaneous injection represents the established administration platform because marketed monoclonal antibodies and siRNA therapies are delivered through injectable formats. The category includes treatment schedules ranging from relatively frequent antibody dosing to longer-duration RNA-interference regimens, while intravenous delivery is relevant to investigational gene-editing approaches; VERVE-102 data showed LDL-C reductions of 53% on average and as high as 69% in its reported 0.6 mg/kg cohort.

Oral therapy represents an emerging competitive pathway rather than the established Indian PCSK9 standard. In 2026, enlicitide became the first FDA-approved oral PCSK9 inhibitor in the United States, with reported LDL-C lowering reaching approximately 60%. India-specific route revenue and route-level CAGR values were not supplied and are therefore not estimated.

By Distribution Channel

Hospital pharmacies are structurally important for specialist-prescribed injectable lipid therapies, particularly among high-risk cardiovascular and genetically confirmed patients. Indian FH literature reports 15% prevalence among premature-CAD patients in the cited North Indian study, while 32% of reported mutations involved LDLR and 2% involved PCSK9, supporting specialist-led identification.

Retail and online pharmacies could become more relevant as self-administered and oral options expand. The emergence of an oral inhibitor capable of approximately 60% LDL-C lowering changes the potential distribution model relative to clinic-administered products. Distribution-channel revenue shares and CAGRs were not provided and are not fabricated.

By Patient Type

Secondary-prevention patients with established ASCVD constitute a strategically important treatment population because aggressive LDL-C lowering is central to recurrent-risk management. The supplied indication data place ASCVD at USD 213.17 million in 2026 and USD 505.97 million by 2034, representing 11.41% CAGR.

Primary-prevention high-risk patients and statin-intolerant patients provide additional expansion potential as dosing becomes less frequent and modality choice increases. HeFH, a major inherited-risk group, reaches USD 858.31 million by 2034 at 11.35% CAGR. Patient-type-specific market values and growth rates were not supplied and therefore remain unquantified.

India PCSK9-Targeted Therapy Market Counties Outlook

Northern, Western, Southern, Eastern and Central India collectively constitute the national opportunity. The supplied tables provide no state- or region-specific revenue allocation, so regional percentage shares are not estimated. At the national level, the supplied modality total rises from USD 733.09 million in 2025 to USD 814.27 million in 2026 and USD 1,886.32 million by 2034, representing 11.07% CAGR.

Western India has documented PCSK9 genetic research activity: a Mumbai-centered study examined 50 FH cases and 50 controls, screened all 12 PCSK9 exons, and detected 8 nonpathogenic PCSK9 variants. Northern India also has epidemiological relevance, with published review evidence reporting FH in 15% of premature-CAD patients in a North Indian prevalence study. However, no supplied dataset quantifies regional production, regional revenue shares or state-level sector splits; assigning percentages would therefore conflict with the mandatory source-data constraint.

Top players in India PCSK9-Targeted Therapy Market

1. Amgen Inc.
2. Novartis AG
3. Sanofi
4. Regeneron Pharmaceuticals, Inc.
5. Merck & Co., Inc.
6. Eli Lilly and Company
7. Verve Therapeutics
8. AstraZeneca
9. Ionis Pharmaceuticals
10. Silence Therapeutics
11. Arrowhead Pharmaceuticals
12. Alnylam Pharmaceuticals
13. CRISPR Therapeutics

Top Two Companies

• Amgen Inc.— Amgen is positioned around evolocumab, one of the established monoclonal-antibody approaches to PCSK9 inhibition and therefore competes within the modality class that represents approximately 45.6% of the supplied Indian 2026 modality value. Company-specific Indian revenue share is not disclosed in the mandatory dataset and no reliable public percentage was identified; accordingly, a proprietary share is not invented. Its positioning rests on an established injectable mechanism and cardiovascular-risk use cases, while competition is intensifying from RNA interference, oral inhibitors and genetic medicines. The broader monoclonal-antibody category grows from USD 371.53 million in 2026 to USD 861.77 million by 2034 at 11.09% CAGR.
• Novartis AG— Novartis is differentiated through inclisiran, an siRNA-based approach that extends PCSK9 suppression beyond conventional antibody dosing schedules. The supplied siRNA category is valued at USD 250.41 million in 2026 and reaches USD 577.48 million by 2034, representing 11.01% CAGR and approximately 30.8% of the supplied 2026 modality total. Company-specific Indian revenue share is not provided in the mandatory tables and cannot be responsibly assigned. Competitive positioning is supported by the long-duration RNA-interference mechanism, particularly where adherence to frequent chronic dosing is challenging, although antibodies, emerging oral inhibitors and one-time genetic approaches are creating increasingly diverse treatment choices.

Recent Developments in India PCSK9-Targeted Therapy Market

• 2026:Merck received U.S. FDA approval for enlicitide/Lipfendra, reported as the first oral PCSK9 inhibitor, with LDL-C reductions of up to approximately 60%, establishing oral delivery as a new competitive modality.
• 2026:Published reporting on VERVE-102 described a 35-patient Phase 1 program with PCSK9 reductions approaching 88% at the highest dose and effects observed for up to approximately 18 months.
• 2025:Verve Therapeutics reported initial Heart-2 Phase 1b results in 14 participants, with mean LDL-C reduction of 53% and maximum reduction of 69% in the 0.6 mg/kg VERVE-102 cohort.
• 2025:VERVE-102's initial clinical dataset reported no treatment-related serious adverse events and no clinically significant ALT or platelet changes among the 14 participants evaluated in the announcement.

Research Methodology

The assessment uses the user-supplied 2025, 2026 and 2034 quantitative tables as the mandatory primary source for market values, segment contributions and CAGRs. Calculated percentages use supplied totals: monoclonal antibodies account for approximately 45.6%, siRNA therapies 30.8% and novel modalities 23.6% of the USD 814.27 million 2026 modality total; HeFH represents approximately 44.5% and ASCVD 26.1% of the USD 815.22 million indication total. External clinical and scientific sources were used only for contextual evidence on epidemiology, technology and recent developments. Where regional, patient-type, route, distribution-channel or company-specific revenue percentages were unavailable, no unsupported values were generated. The slight difference between the supplied 2034 modality total of USD 1,886.32 million and indication total of USD 1,906.51 million is retained exactly as provided rather than reconciled or altered.